Literature DB >> 16889872

Presence of immunoreactive salusin-alpha in human serum and urine.

Kengo Sato1, Takatoshi Koyama, Toru Tateno, Yukio Hirata, Masayoshi Shichiri.   

Abstract

Salusins, identified from a full-length enriched human cDNA library by bioinformatics analyses, show mitogenic, neuromodulatory and hemodynamic activities in rats. They are expressed in a wide variety of human tissues, but their precise structures and levels in human body fluids remain unknown. We developed a radioimmunoassay suitable for the detection of immunoreactive human salusin-alpha and characterized the molecular forms and concentrations of salusin-alpha in human serum and urine. The assay allowed for measurement of immunoreactive salusin-alpha concentrations as low as 1 fmol/tube after extraction of serum with an octyl-silica column, and the concentration required for 50% inhibition of binding was 40 fmol/tube. Cross-reactivities with salusin-beta and other bioactive peptides were negligible. Salusin-alpha-like immunoreactivity in normal human serum and urine ranged from 11.0 to 40.4 pmol/l (mean+/-S.D., 23.3+/-8.1 pmol/l, n=31) and from 18.6 to 367.3 pmol/l (mean+/-S.D., 156.8+/-95.8 pmol/l), respectively. Reverse-phase high performance liquid chromatography coupled with radioimmunoassay detection revealed a major immunoreactive component that coeluted with authentic salusin-alpha. These data indicate the presence of salusin-alpha in human serum and urine, thereby verifying the initially predicted processing sites for salusin-alpha in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16889872     DOI: 10.1016/j.peptides.2006.06.005

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Serum salusin-α levels in systemic lupus erythematosus and systemic sclerosis.

Authors:  Süleyman Serdar Koca; Metin Özgen; Bahar Işık; Mustafa Necati Dağlı; Bilal Üstündağ; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2014-03-01

2.  IS SALUSIN-ALPHA A NEW MARKER OF CARDIOVASCULAR DISEASE RISK IN HYPOTHYROIDISM?

Authors:  H Usta Atmaca; F Akbas
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jan-Mar       Impact factor: 0.877

Review 3.  Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease.

Authors:  Takuya Watanabe; Kengo Sato; Fumiko Itoh; Kohei Wakabayashi; Masayoshi Shichiri; Tsutomu Hirano
Journal:  Sensors (Basel)       Date:  2012-04-18       Impact factor: 3.576

Review 4.  Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases.

Authors:  Kengo Sato; Rena Watanabe; Fumiko Itoh; Masayoshi Shichiri; Takuya Watanabe
Journal:  Int J Hypertens       Date:  2013-10-22       Impact factor: 2.420

5.  Salusin-β Is Involved in Diabetes Mellitus-Induced Endothelial Dysfunction via Degradation of Peroxisome Proliferator-Activated Receptor Gamma.

Authors:  Hai-Jian Sun; Dan Chen; Pei-Yao Wang; Ming-Yu Wan; Chen-Xing Zhang; Zhi-Xuan Zhang; Wei Lin; Feng Zhang
Journal:  Oxid Med Cell Longev       Date:  2017-11-19       Impact factor: 6.543

6.  Salusin-β is superior to salusin-α as a marker for evaluating coronary atherosclerosis.

Authors:  Yuxue Wang; Songjiao Wang; Jun Zhang; Maona Zhang; Hong Zhang; Guofu Gong; Min Luo; Teng Wang; Xiaolu Mao
Journal:  J Int Med Res       Date:  2020-02       Impact factor: 1.671

7.  Salusin-β Mediates High Glucose-Induced Inflammation and Apoptosis in Retinal Capillary Endothelial Cells via a ROS-Dependent Pathway in Diabetic Retinopathy.

Authors:  Hao Wang; Meng Zhang; Hongli Zhou; Lang Cao; Jie Zhou; Qinyun Chen; Xuedong Zhang
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-21       Impact factor: 3.168

8.  Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population?

Authors:  Urszula Kołakowska; Elżbieta Kuroczycka-Saniutycz; Anna Wasilewska; Witold Olański
Journal:  Pediatr Nephrol       Date:  2014-09-23       Impact factor: 3.714

9.  Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator.

Authors:  Kazumi Fujimoto; Akinori Hayashi; Yuji Kamata; Akifumi Ogawa; Takuya Watanabe; Raishi Ichikawa; Yoshitaka Iso; Shinji Koba; Youichi Kobayashi; Takatoshi Koyama; Masayoshi Shichiri
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

10.  Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway.

Authors:  Cheng-Hua Zhou; Lian Liu; Lu Liu; Ming-Xing Zhang; Hao Guo; Jin Pan; Xiao-Xing Yin; Teng-Fei Ma; Yu-Qing Wu
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.